Gila Therapeutics is a Boston-based clinical stage biotech company founded in 2014 that is focused on addressing obesity, type 2 diabetes, and associated metabolic disorders. The company's innovative Topical Lingual Neural Signaling platform allows for the direct activation of specific brain regions responsible for metabolic regulation through the delivery of natural peptide hormones, aiming to minimize side effects. Gila Therapeutics boasts a distinguished scientific advisory team with expertise in endocrinology, neuroscience, and metabolic nephrology. The company recently secured a $355.52K Seed Round investment on 29 November 2022. With its pioneering approach and strong scientific backing, Gila Therapeutics presents an exciting opportunity in the health care industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $355.52K | - | 29 Nov 2022 | |
| Debt Financing | $401.93K | - | 16 Feb 2021 | |
| Venture Round | $314.43K | - | 11 Mar 2019 | |
| Venture Round | $760.16K | - | 18 Apr 2017 | |
| Series A | $3.00M | 4 |
|
28 Feb 2016 |
No recent news or press coverage available for Gila Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
